Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

6.440 +0.120 (+1.90%)
Streaming Delayed Price Updated: 10:48 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 76 companies set new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗
 
Via Benzinga
News headline image
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Why Kezar Life Sciences Shares Are Volatile After Hours ↗
Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading higher in Monday's after-hours session after the company announced that it has received clearance of its Investigational New Drug (IND)... 
Via Benzinga
News headline image
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
From Kezar Life Science
Via Business Wire
News headline image
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating ↗
The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81. 
Via Investor's Business Daily
News headline image
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
From Kezar Life Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.